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Introduction
Anemia in end-stage kidney disease can be managed 
by recombinant human erythropoietin (EPO) (1). Iron 
administration plays a central role in enhancing anemia 
responsiveness to EPO (2). Serum ferritin level and iron 
saturation ratio are the two most commonly used markers 
of iron status in maintenance hemodialysis patients (1-3). Inflammation is quite common in hemodialysis (HD) 
patients, and its prevalence between HD patients may be 
as high as 40 to 60% (3-5). Inflammation, is closely related 
to protein-energy malnutrition in dialysis patients and 
the simultaneous combination of these two conditions, 
also referred to as malnutrition-inflammation syndrome (2-5). It was shown that high levels of serum ferritin are 
engendered by inflammatory status apart from iron stores 
(1-4). Serum ferritin is also an acute phase reactant (3-8). 
While malnutrition-inflammation syndrome may play a 
central role in poor clinical outcome, including a high rate 
of mortality, diminished quality of life and hospitalization, it 
may also lead to high level of ferritin and refractory anemia 
including unresponsiveness to EPO in these patients (6-8). In 
fact, the erythropoiesis suppressing effect of inflammation is 
mainly due to an increased activity of the pro-inflammatory 
cytokines (5-8). In vivo, the cytokines act in concert with 
affect precursor cells at different stages of erythropoiesis. 
Cytokines, TNF-alfa and IL-1 have been studied (2-9). The 
inhibitory effect of TNF-alfa and IL-1 on erythropoiesis can 
be overcome in a dose-dependent fashion by administering 
EPO (2-9). It is thought that the direct inhibitory effect 
on erythroid precursors is primarily due to alterations in 
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The aim of this study was to investigate the association between serum C-reactive 
protein (CRP) as the marker of inflammation with serum ferritin level and its role in the 
severity of anemia of hemodialysis (HD) patients. A cross-sectional study was conducted 
on a group of stable hemodialysis patients. There were 36 patients overall, 25 of which 
were non-diabetic and 11 were diabetic mean patients’ age was 53 (±15.8) years. In this 
study, there was a significant inverse correlation between serum ferritin and hematocrit 
level (r=-0.34, p=0.044) (adjusted for age). Also a significant positive correlation between 
serum CRP and serum iron (r=0.44, p=0.008) (adjusted for age too) was observed. 
Moreover, in male HD patients, a significant positive correlation between serum CRP 
and serum ferritin (r=0.56, p=0.009) was found. Malnutrition and inflammation in 
hemodialysis may increase serum ferritin concentration apart from iron status, and 
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sensitivity to erythropoietin (2-9). C-reactive protein (CRP) 
is secreted by the liver and inflammation causes a rapid 
increase in its serum concentration. It plays a role in the 
host defense by interacting with the complement. Compared 
to measurements of other markers of inflammation and the 
acute-phase reaction, serum CRP has several advantages. 
It is a simple, reliable, readily available and inexpensive 
test. It is also a long-term predictor of cardiovascular risk 
and mortality in general population and in chronic kidney 
disease patients (4-9). It is thought that during the acute 
phase response, inflammatory cytokines such as interleukin 
1 beta (IL-1β) and tumor necrosis factor alpha (TNF-alfa) 
increase the synthesis of both H and L subunits of ferritin. 
Hence, serum ferritin can be elevated in inflammation as 
mentioned above (6-9).
Objectives
We aimed to test the association between serum CRP and 
serum ferritin and its impact on the severity of anemia of 




This cross-sectional study was conducted on a group of end-
stage renal disease patients, who underwent hemodialysis 
treatment The etiologies of renal failure were different, 
containing mainly hypertension, diabetic nephropathy, 
various glomerular diseases, autosomal dominant poly cystic 
kidney disease and also urinary tract infections. According 
to severity of secondary hyperparathyroidism, each patient 
being treated for secondary hyperparathyroidism was given 
oral active vitamin D3 (Rocaltrol), calcium carbonate, and 
Rena-Gel capsules of various doses. According to severity 
of anemia, patients underwent IV iron therapy with iron 
sucrose (Venofer) of various doses after each dialysis session. 
All the patients underwent treatments with 6 mg folic acid 
daily, 500 mg L-Carnitine daily, oral Vitamin B-complex 
tablet daily and also 2000U IV Eprex (recombinant human 
erythropoietin; (rHuEPO) after each routine dialysis session. 
Exclusion criteria were active or chronic infection and using 
NSAID or ACE inhibitor drugs.
Laboratory methods
Complete blood count (hemoglobin & hematocrit level) 
analysis was performed using Sysmex-KX-21N Cell counter. 
Levels of serum iron, total iron binding capacity (TIBC) and 
serum ferritin, CRP and also levels of serum pre-dialysis 
creatinine, post- and pre-dialysis blood urea nitrogen (BUN), 
were measured using standard kits. For the efficacy of 
hemodialysis, the urea reduction rate (URR) was calculated 
from pre- and post-blood urea nitrogen (BUN) data (10). 
Duration and sessions of HD treatment were calculated 
from the patients’ records. Each hemodialysis session was 
in duration of 4 hours. 
Ethical issues
(1) The research followed the tenets of the Declaration 
of Helsinki; (2) informed consent was obtained; (3) the 
research was approved by ethical committee of Shahrekord 
University of Medical Sciences.
Statistical Analysis
For statistical analysis, data are expressed as the mean 
±SD. Statistical correlations were assessed using partial 
correlation test. All statistical analyses were performed 
using SPSS 11.5 (SPSS Inc., Chicago, IL, USA). Statistical 
significance was determined at a p<0.05.
Results
There were 36 patients overall (female=15, male=21). Mean 
patients› age was 53 (±15.8) years. 
In this study, there was a significant inverse correlation 
between serum ferritin and hematocrit level (r=-0.34, 
p=0.044) (adjusted for age). Also a significant positive 
correlation between serum CRP and serum iron (r=0.44, 
p=0.008) (adjusted for age) was observed. Moreover, in 
male HD patients, a significant positive correlation between 
serum CRP and serum ferritin (r=0.56, p=0.009) was 
registered.
Discussion
The important finding of our study was a significant inverse 
correlation between serum ferritin and hematocrit level. 
Also a significant positive correlation between serum CRP 
and serum iron was observed. Moreover, in male HD patients, 
a significant positive correlation between serum CRP and 
serum ferritin was registered.  Anemia  is  a  consistent finding 
in chronic renal disease, affecting up to 90% of patients. The 
central role of anemia in the development of cardiovascular 
dysfunction is now well-known (1-5). Anemia of HD can 
be managed relatively successfully by recombinant human 
erythropoietin. Iron administration plays a central role in 
enhancing anemia responsiveness to EPO. Serum ferritin 
concentration is a commonly used marker of iron status 
in maintenance dialysis patients (1-3). It was shown that 
a low serum ferritin concentration is a reliable indicator of 
iron deficiency among HD patients. However, a high serum 
ferritin may not be an optimal indicator of increased iron 
stores among dialysis patients, because it is an acute-phase 
reactant and its increase in dialysis patients may be based 
on the factor unrelated to iron stores such as inflammation (3-8). In dialysis patients, high CRP levels are associated 
with low hemoglobin levels and/or EPO resistance (11-13). 
In the study conducted by Sirken et al. it was found that the 
increased levels of CRP were associated with relative EPO 
resistance in dialysis patients (14). Our findings support 
the first direct evidence that inflammation, which is closely 
related to protein-energy malnutrition (3-8) in dialysis 
patients, might affect anemia toward its intensification. 
Our data support the evidence that inflammation may not 
have an effect on serum ferritin, unless there is enough 
iron stores in the body, so that serum ferritin is somewhat 
increased (2-7). Rogers et al. showed that IL-1β induces 
ferritin gene expression by translational control of its mRNA. 
However, this inflammatory induction of ferritin synthesis is 
different from iron-dependent ferritin gene expression (9). 
They showed that this inflammatory regulation of ferritin 
requires the background presence of cellular iron (9). In 
other words, without adequate iron stores, serum ferritin 
is low and does not correlate with inflammation, but with 
enough iron, serum ferritin has the function of both iron 
and inflammation (2). Kalantar-Zadeh et al. in a study on of 
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82 HD patients, showed that serum ferritin concentrations 
were higher in malnourished patients (15). 
Conclusion
In summary, we can conclude that Malnutrition-
inflammation complex syndrome may increase serum 
ferritin concentration apart from iron status, and needs 
more attention during iron therapy for the treatment of 
anemia in regular HD patients. 
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